- Osprey Medical (OSP) has received CE Marking approval for its second-generation DyeVert Power XT device
- This approval means the product can now marketed and sold across Europe, which aligns with the company’s strategy
- The main feature of the new device is its compatibility with automated power injectors
- Monitoring the amount of dye used is important in reducing a patient’s risk for dye-related kidney damage
- A recently published study by Dr Carlo Briguori found a 38 per cent dye reduction in patients who received DyeVert compared to the no-DyeVert group
- Company shares are up 8.57 per cent and trading for 3.8 cents
